A Cross-Cultural Study of Depression in the Aftermath of a Natural Disaster

This study evaluated the extent and severity of depressive symptoms among adults (n=1015) in Armenia one year after the 1988 earthquake, using an Armenian translation of the Beck Depression Inventory (BDI-Arm). Earthquake surivivors had higher levels of depression than did their non-earthquake counterparts. For both the quake and non-quake regions, women were found to have higher scores on the BDI-Arm than men, and persons between the ages of 31–55 reported significantly higher depressive ratings than individuals who were 17–30. Interactions between the quake and non-quake areas and gender indicated that women in both areas reported significantly more depressive symptoms than men. The psychometric properties of the BDI-Arm compared favorably to those defined by North American studies.     

LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress

Metabotropic glutamate (mGlu) receptors, which include mGlu1-8 receptors, are a heterogeneous family of G-protein coupled receptors (GPCRs) that function to modulate neuronal excitation and plasticity via pre-synaptic, post-synaptic and glial mechanisms. Agonists for group II mGlu receptors (mGlu2 and mGlu3), such as LY354740, have been shown to suppress enhanced glutamatergic excitations in brain synapses known to be involved in the expression of fear/anxiety in animals and humans. Systemic administration of LY354740 increases open-arm time in the elevated plus maze in mice under conditions of moderate to severe stress, blocks the expression but not development of fear-potentiated startle in rats, prevents lactate-induced panic-like responses in panic-prone rats, and attenuates certain physiological, behavioral, and neurochemical consequences of acute stress in rodents. In these preclinical models, LY354740 does not produce the side-effects (e.g. sedation) that are associated with other anxiolytic agents such as benzodiazepines. Early clinical results with LY354740 have demonstrated safety and efficacy in a human anxiety model (panic provocation induced by CO2 challenge). Collectively, these data indicate mGlu2/3 receptor agonists such as LY354740 represent a promising new approach for treatment of anxiety and stress-related disorders in humans.